EcoDrugPlus

Natriuretic Peptide Receptor 1b

Ensembl ID : ENSDARG00000018750
Gene Symbol: NPR1B
5 Cross references
191 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSDARG00000104393
Gene Symbol: NPR2
3 Enzyme and pathways 5 Cross references
185 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSDARG00000035253
Gene Symbol: NPR3
5 Cross references
210 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSDARG00000101522
Gene Symbol: LOC101882451
6 Enzyme and pathways 5 Cross references
186 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSDARG00000094763
Gene Symbol: NPY2R
4 Cross references
183 Possible Orthologues:

Neuropeptide Y Receptor Y2, Like

Ensembl ID : ENSDARG00000089943
Gene Symbol: NPY2RL
7 Enzyme and pathways 5 Cross references
178 Possible Orthologues:

Neuropeptide Y Receptor Y4

Ensembl ID : ENSDARG00000043341
Gene Symbol: NPY4R
7 Enzyme and pathways 5 Cross references
137 Possible Orthologues:

Neurotensin Receptor 1 (High Affinity)

Ensembl ID : ENSDARG00000077577
Gene Symbol: NTSR1
7 Enzyme and pathways 5 Cross references
200 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSDARG00000004586
Gene Symbol: NTRK1
12 Enzyme and pathways 5 Cross references
200 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2a

Ensembl ID : ENSDARG00000059897
Gene Symbol: NTRK2A
8 Enzyme and pathways 5 Cross references
210 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSDARG00000098511
Gene Symbol: NTRK2B
5 Cross references
213 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 3a

Ensembl ID : ENSDARG00000077228
Gene Symbol: NTRK3A
7 Enzyme and pathways 5 Cross references
157 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).